On Oct. 7, 2020, Kindred Biosciences announced it had expanded an agreement with Vaxart for the manufacture of Vaxartﾒs oral vaccine for COVID-19 and other vaccine candidates. The manufacturing services will be performed via Centaur Biopharmaceutical Services, a wholly owned subsidiary of KindredBio that provides full service contract development and manufacturing services.